Dinah, ClinkShrink, & Roy produce Shrink Rap: a blog by Psychiatrists for Psychiatrists, interested bystanders are also welcome. A place to talk; no one has to listen.
Saturday, September 30, 2006
FDA Drugs: Sept 2006
Just a quick list of relevant FDA and related notices...
Lamictal & Pregnancy: cleft lip in first trimester... see also Neurology abstract reviewing risk of fetal abnormalities in 4 anticonvulsants (note: take numbers with grain of salt... the N for each drug exposure is kinda low)
Generic Topamax released
Effexor label revised: mentions risk of serotonin syndrome with triptans
Abilify 7.5mg injectable: approved for agitation associated with schizophrenia and bipolar disorder
Contrave advances: New obesity drug... combines Wellbutin/bupropion and Revia/naltrexone to cause weight loss... 6-month trial in 250 people results in 7.5% wt loss (vs 1% for placebo). [see also Orexigen site]
Labels:
abilify,
effexor,
FDA,
lamictal,
side effects
Subscribe to:
Post Comments (Atom)
8 comments:
I cringe everytime I see that name, Abilify. Who thinks up these things? Lol.
Hmmm, on the Contrave, what are the doses used of the components? And where does one sign up?
--
How come we don't do this every month??
It'd be cool if you did.
Sorry! I thought you might write about [deleted comment] here. Didn't mean to offend.
Plus, the drug naming thing was kinda interesting, no?
Ok, so I'll try to do this more often. Pharmacology is my thing, so I'm glad to oblige.
Post a Comment